MedTrace Logo

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

NCT04688151 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-22

No results posted yet for this study

Summary

To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL

Conditions

  • Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG

Rituximab

Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Shang-Ju Wu, M.D · National Taiwan University Hospital, Taipei, Taiwan

  • Su-Peng Yeh, M.D · China Medical University Hospital

  • Kwang-Yu Chang, M.D · National Cheng Kung University Hospital,Taiwan

  • Ming Chung Wang, M.D · Chang Gung Memorial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04688151 on ClinicalTrials.gov